Antibody to Renalase
The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics.
1. A composition comprising an isolated monoclonal antibody, wherein the antibody comprises: a) the heavy chain CDR1 sequence of SEQ ID NO:35; b) the heavy chain CDR2 sequence of SEQ ID NO:36; c) the heavy chain CDR3 sequence of SEQ ID NO:37; d) the light chain CDR1 sequence of SEQ ID NO:38; e) the light chain CDR2 sequence of SEQ ID NO:39; and f) the light chain CDR3 sequence of SEQ ID NO:40.
2. The composition of claim 1 , wherein the antibody specifically binds to renalase with an affinity of at least 10 −6 M.
3. The composition of claim 1 , wherein the antibody specifically binds a peptide sequence as set forth in SEQ ID NO:6.
4. The composition of claim 1 , wherein the antibody is selected from the group consisting of an immunoconjugate, a defucosylated antibody, and a bispecific antibody.
5. The composition of claim 4 , wherein the immunoconjugate comprises a therapeutic agent or a detection moiety.
6. The composition of claim 1 , wherein the antibody is selected from the group consisting of a humanized antibody, a chimeric antibody, a fully human antibody, and an antibody mimetic.
7. The composition of claim 1 , wherein the antibody comprises a heavy chain sequence as set forth in SEQ ID NO:33.
8. The composition of claim 1 , wherein the antibody comprises a light chain sequence as set forth in SEQ ID NO:34.